Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus far, it is unclear to what extent CETP is causally related to measures of atherosclerosis.
|
29174438 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The randomized placebo-controlled REVEAL trial demonstrated the clinical efficacy of the CETP inhibitor anacetrapib among patients with pre-existing atherosclerotic vascular disease.
|
31331193 |
2019 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis.
|
23891427 |
2013 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the ILLUMINATE Trial, treatment with the cholesteryl ester transfer protein inhibitor torcetrapib resulted in a significant increase in both atherosclerotic cardiovascular disease events and total mortality which was not explained by changes in the routinely measured plasma lipids.
|
28431663 |
2017 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Enhanced and diminished atherosclerosis have been associated with plasma levels of cholesteryl ester transfer protein (CETP); however, little is known about the role of CETP-ovarian hormone interactions in atherogenesis.
|
12518020 |
2003 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study helped address some of the controversies regarding the relationship of serum CETP mass to atherosclerosis, in addition to the association of ACS occurrence with circulating CETP levels.
|
31504738 |
2020 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The effects of two common polymorphisms of CETP, TaqIB in intron 1 and isoleucine 405 to valine (I405-->V) in exon 14, were examined in a sample of 822 men age 18-28 years from 11 countries in Europe who had participated in a study (the European Atherosclerosis Research Study II) of the offspring of myocardial infarction sufferers before the age of 55 years and age-matched control subjects.
|
10092998 |
1999 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
|
23625977 |
2014 |
Atherosclerosis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis.
|
28096968 |
2016 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taq1B polymorphism of cholesteryl ester transfer protein (CETP) is believed to associate with high-density lipoprotein-cholesterol (HDL-C) levels and may alter the susceptibility to atherosclerosis.
|
20799898 |
2010 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because lack of cholesteryl ester transfer protein (CETP) is a major difference between murine and humans in lipoprotein metabolism, we aimed to create a novel Syrian Golden hamster model deficient in LCAT activity, which expresses endogenous CETP, to explore its metabolic features and particularly the influence of LCAT on the development of atherosclerosis.
|
29526535 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma cholesteryl ester transfer protein has a dual effect on atherosclerosis, depending on the metabolic background.
|
10945721 |
2000 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite similar atherosclerosis development, E3L.CETP mice had lower HDL-cholesterol as compared to E3L-HC mice (-49%) indicating that the HDL-cholesterol lowering effect of CETP is unlikely to contribute to atherosclerosis development in this experimental setting.
|
19345354 |
2009 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
By shifting cholesterol in plasma from HDL to (V)LDL in exchange for VLDL-TG, CETP aggravates atherosclerosis in hyperlipidemic APOE*3-Leiden (E3L) mice.
|
19564641 |
2010 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, CETP inhibitors have attracted considerable interest in atherosclerosis-related disease.
|
29424255 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that increased plasma CETP mass concentrations could lead to significant LDL particle remodeling in FH heterozygotes and could contribute to the pathogenesis of atherosclerosis.
|
15026427 |
2004 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further studies are necessary for understanding of the role of CETP in lipid metabolism and the development of novel therapies involving a combination of strategies for treatment of atherosclerosis and cardiovascular disease.
|
18620517 |
2008 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, inulin did not reduce hypercholesterolemia or atherosclerosis development in E3L.CETP mice despite showing clear prebiotic activity, but resulted in manifestations of hepatic inflammation when combined with a high percentage of dietary cholesterol.
|
30409998 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of cholesteryl ester transfer protein (CETP) in the development of atherosclerosis is under debate.
|
22854712 |
2012 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Decreasing CETP activity has consistently inhibited atherosclerosis in animal models.
|
21122682 |
2011 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have screened the CETP gene for mutations and polymorphisms regulating high density lipoproteins cholesterol (HDL-C) levels and the development of atherosclerosis, and found some polymorphisms (I405V and R451Q) to have minor effects.
|
11454014 |
2001 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we report a reduction in atherosclerosis in response to pharmacological stimulation of thermogenesis linked to increased HDL levels in APOE*3-Leiden.CETP mice.
|
28422089 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cholesteryl Ester Transfer Protein (CETP) is an important therapeutic target for the treatment of atherosclerotic cardiovascular disease.
|
27750148 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
|
26683793 |
2016 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This article reviews the physiology of CETP in lipoprotein metabolism and the data in animals and humans that are relevant to the question of whether CETP inhibition may some day be part of the clinical armamentarium for treating dyslipidemia and atherosclerotic vascular disease.
|
15296707 |
2004 |